A well-recognized gap exists in the path from biomedical discovery in academia to clinical application and commercialization of therapeutic, device, and diagnostic technologies in cardiovascular, pulmonary, hematologic, and sleep disorders. This chasm is the result of inadequate funding for support of proof-of-concept or validation studies essential for early stage development; insufficient access to the resources and expertise needed to develop new technologies; and a lack of knowledge and experience among academic investigators in bringing new ideas to commercial realization. Within the partnering institutions included in this application, the essential elements exist with which to build the infrastructure needed to support and sustain the uninterrupted, durable flow of inventions from discovery through development and commercialization. While these institutions have a clear track record of remarkably successful development of many biomedical technologies, most of these commercial successes have been achieved by the tenacity of individual inventors rather than with the help of committed institutional mechanisms. We proposed to address these key shortcomings by establishing the regional Boston Center for Accelerated Innovation in Therapeutics, Devices, and Diagnostics for Heart, Lung, Blood, and Sleep Disorders (B-BIC, or the Boston Biomedical Innovation Center). The key objectives of this Center are to: 1) develop an integrated infrastructure that would expand the universe of commercializable technologies for heart, lung, blood, and sleep disorders; 2) place these opportunities in the proper evaluative context through an engagement (seed it), solicitation (find it), and selection (pick it) strategy; 3) efficiently and effectively bring those selected to an appropriate exit point from the development process; and 4) provide the educational and mentoring infrastructure necessary for the development of the proper entrepreneurial skills among academic innovators. By achieving these goals, B-BlC would change the culture of our academic environment, as well as the relationship between the public and private sectors in facilitating successful development strategies for technologies in heart, lung, blood, and sleep disorders for the ultimate benefit of patients and society.

Public Health Relevance

Translation of basic observations into clinical practice is limited by the resources needed for development, inadequate experience of academic investigators, and the discovery-focused academic culture. Building an academic infrastructure that facilitates translation by promoting development is an important goal to ensure the successful translation of research into benefit for patients and society.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
3U54HL119145-05S1
Application #
9566387
Study Section
Special Emphasis Panel (ZHL1)
Program Officer
Rousche, Kathleen T
Project Start
2013-09-26
Project End
2020-07-31
Budget Start
2017-09-20
Budget End
2018-07-31
Support Year
5
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Yu, Binglan; Ferrari, Michele; Schleifer, Grigorij et al. (2018) Development of a portable mini-generator to safely produce nitric oxide for the treatment of infants with pulmonary hypertension. Nitric Oxide 75:70-76
Libby, Peter; Loscalzo, Joseph; Ridker, Paul M et al. (2018) Inflammation, Immunity, and Infection in Atherothrombosis: JACC Review Topic of the Week. J Am Coll Cardiol 72:2071-2081
Yang, Jia-Shu; Hsu, Jia-Wei; Park, Seung-Yeol et al. (2018) GAPDH inhibits intracellular pathways during starvation for cellular energy homeostasis. Nature 561:263-267
Schmidt, Ehud J; Halperin, Henry R (2018) MRI use for atrial tissue characterization in arrhythmias and for EP procedure guidance. Int J Cardiovasc Imaging 34:81-95
Gale, Eric M; Wey, Hsiao-Ying; Ramsay, Ian et al. (2018) A Manganese-based Alternative to Gadolinium: Contrast-enhanced MR Angiography, Excretion, Pharmacokinetics, and Metabolism. Radiology 286:865-872
Samokhin, Andriy O; Stephens, Thomas; Wertheim, Bradley M et al. (2018) NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension. Sci Transl Med 10:
Antman, Elliott M; Di Corleto, Paul E; Freeman, Mason W et al. (2017) NIH Centers for Accelerated Innovations Program: principles, practices, successes and challenges. Nat Rev Drug Discov 16:663-664
Savage, William J; Burns, John R; Fiering, Jason (2017) Safety of acoustic separation in plastic devices for extracorporeal blood processing. Transfusion 57:1818-1826
Horvath, Markus A; Wamala, Isaac; Rytkin, Eric et al. (2017) An Intracardiac Soft Robotic Device for Augmentation of Blood Ejection from the Failing Right Ventricle. Ann Biomed Eng 45:2222-2233
Zazzeron, Luca; Liu, Chen; Franco, Walfre et al. (2017) Pulmonary Phototherapy to Treat Carbon Monoxide Poisoning in Rats. Shock 47:735-742

Showing the most recent 10 out of 26 publications